Cancer & SURVIVEiT News
Category Filter:
FDA approves combo KEYTRUDA + LENVIMA for some endometrial carcinoma patients
On September 17, 2019, the Food and Drug Administration granted accelerated approval to the combination of pembrolizumab (KEYTRUDA, Merck) plus lenvatinib (LENVIMA, Eisai) for the treatment of patients with advanced…